Assessment of Drug–Drug Interaction Risk Between Intravenous Fentanyl and the Glecaprevir/Pibrentasvir Combination Regimen in Hepatitis C Patients Using Physiologically Based Pharmacokinetic Modeling and Simulations

World Health Organization (WHO). Global progress report on HIV, viral hepatitis and sexually transmitted infections, 2021. Accountability for the global health sector strategies 2016–2021: actions for impact. 2021. https://www.who.int/publications/i/item/9789240027077 . Accessed March 2023. citation_journal_title=Lancet Gastroenterol Hepatol; citation_title=The contribution of injection drug use to hepatitis C virus transmission globally, regionally, and at country level: a modelling study; citation_author=A Trickey, H Fraser, AG Lim, A Peacock, S Colledge, JG Walker; citation_volume=4; citation_issue=6; citation_publication_date=2019; citation_pages=435-444; citation_doi=10.1016/S2468-1253(19)30085-8; citation_id=CR2 citation_journal_title=Lancet Gastroenterol Hepatol; citation_title=Prevalence and incidence of hepatitis C virus infection in men who have sex with men: a systematic review and meta-analysis; citation_author=F Jin, GJ Dore, G Matthews, N Luhmann, V Macdonald, S Bajis; citation_volume=6; citation_issue=1; citation_publication_date=2021; citation_pages=39-56; citation_doi=10.1016/S2468-1253(20)30303-4; citation_id=CR3 Conway B, Truong D, Yamamoto L, Yung R, Sharma S. Use of glecaprevir/pibrentasvir (G/P) for the treatment of HCV infection among fentanyl users: an interim analysis of the GRAND PLAN study. J Hepatol. 2022;77:S553. Moga T, Nallapeta N, Martinez A, editors. Variable adherence to HCV treatment among people who inject drugs treated with 8 versus 12 weeks of antiviral therapy resulted in high rates of SVR12 and reinfection rate was low. In: The Liver Meeting American Association for The Study Of Liver Disease, AASLD, 2022 Nov 4–8; Washington, DC, USA. Datapharm Ltd. Electronic Medicine Compendium (EMC). Matrifen 75 micrograms/hour Transdermal patch. 2023. https://www.medicines.org.uk/emc/product/10272/ . Accessed March 2023. Datapharm Ltd. Electronic Medicine Compendium (EMC). Fentanyl 50 microgram/ml injection. 2022. https://www.medicines.org.uk/emc/product/2852/smpc#gref . Accessed March 2023. Centers for Disease Control and Prevention (CDC). Fentanyl. 2022. https://www.cdc.gov/opioids/basics/fentanyl.html . Accessed March 2023. Ramos-Matos CF, Bistas KG, Lopez-Ojeda W. Fentanyl. Treasure Island: StatPearls Publishing; 2022. citation_journal_title=J Pain; citation_title=The fentanyl story; citation_author=TH Stanley; citation_volume=15; citation_issue=12; citation_publication_date=2014; citation_pages=1215-1226; citation_doi=10.1016/j.jpain.2014.08.010; citation_id=CR10 citation_journal_title=Drug Saf; citation_title=Benefit-risk assessment of transdermal fentanyl for the treatment of chronic pain; citation_author=CA Kornick, J Santiago-Palma, N Moryl, R Payne, EA Obbens; citation_volume=26; citation_issue=13; citation_publication_date=2003; citation_pages=951-973; citation_doi=10.2165/00002018-200326130-00004; citation_id=CR11 Drug Enforcement Administration. National drug threat assessment. 2019. https://www.dea.gov/sites/default/files/2020-01/2019-NDTA-final-01-14-2020_Low_Web-DIR-007-20_2019.pdf . Accessed 2023 March. Centers for Disease Control and Prevention (CDC). The facts about fentanyl. 2022. https://www.cdc.gov/stopoverdose/fentanyl/index.html . Accessed Mar 2023. Centers for Disease Control and Prevention (CDC). U.S. overdose deaths in 2021 increased half as much as in 2020—but are still up 15%. 2022. https://www.cdc.gov/nchs/pressroom/nchs_press_releases/2022/202205.htm . Accessed March 2023. citation_journal_title=Int J Drug Policy; citation_title=Fentanyl in the US heroin supply: a rapidly changing risk environment; citation_author=D Ciccarone; citation_publication_date=2017; citation_doi=10.1016/j.drugpo.2017.06.010; citation_id=CR15 citation_journal_title=Clin Toxicol; citation_title=Self-identification of nonpharmaceutical fentanyl exposure following heroin overdose; citation_author=MK Griswold, PR Chai, AJ Krotulski, M Friscia, B Chapman, EW Boyer; citation_volume=56; citation_issue=1; citation_publication_date=2018; citation_pages=37-42; citation_doi=10.1080/15563650.2017.1339889; citation_id=CR16 citation_journal_title=Addiction; citation_title=Illicit fentanyls in the opioid street market: desired or imposed?; citation_author=SG Mars, D Rosenblum, D Ciccarone; citation_volume=114; citation_issue=5; citation_publication_date=2019; citation_pages=774-780; citation_doi=10.1111/add.14474; citation_id=CR17 citation_journal_title=Drug Metab Dispos; citation_title=Metabolism of fentanyl, a synthetic opioid analgesic, by human liver microsomes. Role of CYP3A4; citation_author=DE Feierman, JM Lasker; citation_volume=24; citation_issue=9; citation_publication_date=1996; citation_pages=932-939; citation_id=CR18 citation_journal_title=Br J Clin Pharmacol; citation_title=A review of factors explaining variability in fentanyl pharmacokinetics; focus on implications for cancer patients; citation_author=EJ Kuip, ML Zandvliet, SL Koolen, RH Mathijssen, CC Rijt; citation_volume=83; citation_issue=2; citation_publication_date=2017; citation_pages=294-313; citation_doi=10.1111/bcp.13129; citation_id=CR19 US Food and Drug Administration (FDA). Drug development and drug interactions: table of substrates, inhibitors and inducers. 2022. https://www.fda.gov/drugs/developmentapprovalprocess/developmentresources/druginteractionslabeling/ucm093664.htm . Accessed March 2023. citation_journal_title=Hum Genom; citation_title=A useful tool for drug interaction evaluation: the University of Washington Metabolism and Transport Drug Interaction Database; citation_author=H Hachad, I Ragueneau-Majlessi, RH Levy; citation_volume=5; citation_issue=1; citation_publication_date=2010; citation_pages=1-12; citation_doi=10.1186/1479-7364-5-1-61; citation_id=CR21 European Medicines Agency (EMA). Guideline on the investigation of drug interactions. 2012. https://www.ema.europa.eu/documents/scientific-guideline/guideline-investigation-drug-interactions_en.pdf . Accessed March 2023. citation_journal_title=Anesthesiology; citation_title=Ritonavir's role in reducing fentanyl clearance and prolonging its half-life; citation_author=KT Olkkola, VJ Palkama, PJ Neuvonen; citation_volume=91; citation_issue=3; citation_publication_date=1999; citation_pages=681-685; citation_doi=10.1097/00000542-199909000-00020; citation_id=CR23 citation_journal_title=Eur J Clin Pharmacol; citation_title=Effect of voriconazole and fluconazole on the pharmacokinetics of intravenous fentanyl; citation_author=TI Saari, K Laine, M Neuvonen, PJ Neuvonen, KT Olkkola; citation_volume=64; citation_issue=1; citation_publication_date=2007; citation_pages=25-30; citation_doi=10.1007/s00228-007-0398-x; citation_id=CR24 citation_journal_title=Anesth Analg; citation_title=The effect of the systemic antimycotics, itraconazole and fluconazole, on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam; citation_author=KT Olkkola, J Ahonen, PJ Neuvonen; citation_volume=82; citation_issue=3; citation_publication_date=1996; citation_pages=511-516; citation_id=CR25 citation_journal_title=Br J Clin Pharmacol; citation_title=Ritonavir is the best alternative to ketoconazole as an index inhibitor of cytochrome P450–3A in drug–drug interaction studies; citation_author=DJ Greenblatt, JS Harmatz; citation_volume=80; citation_issue=3; citation_publication_date=2015; citation_pages=342-350; citation_doi=10.1111/bcp.12668; citation_id=CR26 citation_journal_title=Sci Rep; citation_title=Minor contribution of cytochrome P450 3A activity on fentanyl exposure in palliative care cancer patients; citation_author=MJ Geist, VC Ziesenitz, HJ Bardenheuer, J Burhenne, G Skopp, G Mikus; citation_volume=9; citation_issue=1; citation_publication_date=2019; citation_pages=1-6; citation_doi=10.1038/s41598-019-51279-6; citation_id=CR27 citation_journal_title=Br J Anaesth; citation_title=The CYP 3A4 inhibitor itraconazole has no effect on the pharmacokinetics of iv fentanyl; citation_author=VJ Palkama, PJ Neuvonen, KT Olkkola; citation_volume=81; citation_issue=4; citation_publication_date=1998; citation_pages=598-600; citation_doi=10.1093/bja/81.4.598; citation_id=CR28 AbbVie. Mavyret: US package insert. 2021. https://www.rxabbvie.com/pdf/mavyret_pi.pdf . Accessed March 2023. AbbVie. Maviret: EU summary of product characteristics. 2021. https://www.ema.europa.eu/en/documents/product-information/maviret-epar-product-information_en.pdf . Accessed March 2023. citation_journal_title=NPJ Syst Biol Appl; citation_title=Integration of genome-scale metabolic networks into whole-body PBPK models shows phenotype-specific cases of drug-induced metabolic perturbation; citation_author=H Cordes, C Thiel, V Baier, LM Blank, L Kuepfer; citation_volume=4; citation_issue=1; citation_publication_date=2018; citation_pages=1-11; citation_doi=10.1038/s41540-018-0048-1; citation_id=CR31 citation_journal_title=Drug Metab Dispos; citation_title=Physiologically based pharmacokinetic model predictions of panobinostat (LBH589) as a victim and perpetrator of drug-drug interactions; citation_author=HJ Einolf, W Lin, CS Won, L Wang, H Gu, DY Chun; citation_volume=45; citation_issue=12; citation_publication_date=2017; citation_pages=1304-1316; citation_doi=10.1124/dmd.117.076851; citation_id=CR32 citation_journal_title=J Clin Pharmacol; citation_title=Quantitative prediction of the effect of CYP3A inhibitors and inducers on venetoclax pharmacokinetics using a physiologically based pharmacokinetic model; citation_author=KJ Freise, M Shebley, AH Salem; citation_volume=57; citation_issue=6; citation_publication_date=2017; citation_pages=796-804; citation_doi=10.1002/jcph.858; citation_id=CR33 Zhang X, Yang Y, Grimstein M, Fan J, Grillo JA, Huang SM, et al. Application of PBPK modeling and simulation for regulatory decision making and its impact on US prescribing information: an update on the 2018–2019 submissions to the US FDA’s Office of Clinical Pharmacology. J Clin Pharmacol. 2020;60:S160–78. citation_journal_title=CPT Pharmacomet Syst Pharmacol; citation_title=Predictive performance of physiologically based pharmacokinetic and population pharmacokinetic modeling of renally cleared drugs in children; citation_author=W Zhou, T Johnson, H Xu, S Cheung, K Bui, J Li; citation_volume=5; citation_issue=9; citation_publication_date=2016; citation_pages=475-483; citation_doi=10.1002/psp4.12101; citation_id=CR35 citation_journal_title=Thromb J; citation_title=Pharmacokinetics of rivaroxaban in children using physiologically based and population pharmacokinetic modelling: an EINSTEIN-Jr phase I study; citation_author=S Willmann, K Thelen, D Kubitza, AW Lensing, M Frede, K Coboeken; citation_volume=16; citation_issue=1; citation_publication_date=2018; citation_pages=1-12; citation_doi=10.1186/s12959-018-0185-1; citation_id=CR36 citation_journal_title=J Pharm Sci; citation_title=Food effect projections via physiologically based pharmacokinetic modeling: predictive case studies; citation_author=C Tistaert, T Heimbach, B Xia, N Parrott, TS Samant, F Kesisoglou; citation_volume=108; citation_issue=1; citation_publication_date=2019; citation_pages=592-602; citation_doi=10.1016/j.xphs.2018.05.024; citation_id=CR37 citation_journal_title=Expert Opin Drug Metab Toxicol; citation_title=The Simcyp® population-based ADME simulator; citation_author=M Jamei, S Marciniak, K Feng, A Barnett, G Tucker, A Rostami-Hodjegan; citation_volume=5; citation_issue=2; citation_publication_date=2009; citation_pages=211-223; citation_doi=10.1517/17425250802691074; citation_id=CR38 citation_journal_title=Drugs R&D; citation_title=Prediction of drug–drug interactions between opioids and overdosed benzodiazepines using physiologically based pharmacokinetic (PBPK) modeling and simulation; citation_author=B Ji, S Liu, Y Xue, X He, VH Man, X-Q Xie; citation_volume=19; citation_issue=3; citation_publication_date=2019; citation_pages=297-305; citation_doi=10.1007/s40268-019-00282-3; citation_id=CR39 citation_journal_title=Pharmaceutics; citation_title=Physiologically-based pharmacokinetic (PBPK) modeling providing insights into fentanyl pharmacokinetics in adults and pediatric patients; citation_author=L Kovar, A Weber, M Zemlin, Y Kohl, R Bals, B Meibohm; citation_volume=12; citation_issue=10; citation_publication_date=2020; citation_pages=908; citation_doi=10.3390/pharmaceutics12100908; citation_id=CR40 Shankaran H, Adeshina F, Teeguarden JG. Physiologically-based pharmacokinetic model for fentanyl in support of the development of provisional advisory levels. Toxicol Appl Pharmacol. 2013;273(3):464–76. citation_journal_title=J Pharmacokinet Pharmacodyn; citation_title=Reduction and lumping of physiologically based pharmacokinetic models: prediction of the disposition of fentanyl and pethidine in humans by successively simplified models; citation_author=S Björkman; citation_volume=30; citation_issue=4; citation_publication_date=2003; citation_pages=285-307; citation_doi=10.1023/A:1026194618660; citation_id=CR42 citation_journal_title=J Clin Pharmacol; citation_title=Pharmacokinetic interaction of intravenous fentanyl with ketoconazole; citation_author=VC Ziesenitz, SK König, NS Mahlke, G Skopp, WE Haefeli, G Mikus; citation_volume=55; citation_issue=6; citation_publication_date=2015; citation_pages=708-717; citation_doi=10.1002/jcph.469; citation_id=CR43 citation_journal_title=Anesth Analg; citation_title=Age and fentanyl pharmacokinetics; citation_author=JB Bentley, JD Borel, RE Nenad, TJ Gillespie; citation_volume=61; citation_issue=12; citation_publication_date=1982; citation_pages=968-971; citation_doi=10.1213/00000539-198212000-00002; citation_id=CR44 citation_journal_title=Br J Anaesth; citation_title=Plasma fentanyl concentrations and the occurrence of respiratory depression in volunteers; citation_author=H Stoeckel, J Schüttler, H Magnussen, J Hengstmann; citation_volume=54; citation_issue=10; citation_publication_date=1982; citation_pages=1087-1095; citation_doi=10.1093/bja/54.10.1087; citation_id=CR45 citation_journal_title=Clin Ther; citation_title=Pharmacokinetics, efficacy, and tolerability of fentanyl following intranasal versus intravenous administration in adults undergoing third-molar extraction: a randomized, double-blind, double-dummy, two-way, crossover study; citation_author=LL Christrup, D Foster, LD Popper, T Troen, R Upton; citation_volume=30; citation_issue=3; citation_publication_date=2008; citation_pages=469-481; citation_doi=10.1016/j.clinthera.2008.03.001; citation_id=CR46 citation_journal_title=Br J Clin Pharmacol; citation_title=Pulmonary administration of aerosolised fentanyl: pharmacokinetic analysis of systemic delivery; citation_author=LE Mather, A Woodhouse, ME Ward, SJ Farr, RA Rubsamen, LG Eltherington; citation_volume=46; citation_issue=1; citation_publication_date=1998; citation_pages=37-43; citation_doi=10.1046/j.1365-2125.1998.00035.x; citation_id=CR47 citation_journal_title=J Clin Pharmacol; citation_title=Quinidine as a probe for the role of p-glycoprotein in the intestinal absorption and clinical effects of fentanyl; citation_author=ED Kharasch, C Hoffer, TG Altuntas, D Whittington; citation_volume=44; citation_issue=3; citation_publication_date=2004; citation_pages=224-233; citation_doi=10.1177/0091270003262075; citation_id=CR48 Mukherjee D, Kosloski M, Liu W, Shebley M. Physiologically based pharmacokinetic modeling of glecaprevir and pibrentasvir as a combination: mechanistic modeling of non-linear pharmacokinetics. Poster presentation (PII-099) at ASCPT Annual Meeting, 2018 Mar 21–24; Orlando, FL, USA. citation_journal_title=Drug Metab Dispos; citation_title=Critique of the two-fold measure of prediction success for ratios: application for the assessment of drug-drug interactions; citation_author=EJ Guest, L Aarons, JB Houston, A Rostami-Hodjegan, A Galetin; citation_volume=39; citation_issue=2; citation_publication_date=2011; citation_pages=170-173; citation_doi=10.1124/dmd.110.036103; citation_id=CR50 Center for Drug Evaluation and Research. Clinical pharmacology and biopharmaceutics review(s). 2017. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209394orig1s000clinpharmr.pdf . citation_journal_title=J Hepatol; citation_title=ABT-493 and ABT-530 combination demonstrated minimal potential for CYP-mediated drug-drug interactions; citation_author=M Kosloski, S Dutta, D Pugatch, H Li, F Mensa, J Kort; citation_volume=2; citation_issue=64; citation_publication_date=2016; citation_pages=S405; citation_id=CR52 citation_journal_title=Liver Int; citation_title=Real-life glecaprevir/pibrentasvir in a large cohort of patients with hepatitis C virus infection: the MISTRAL study; citation_author=M Persico, A Aglitti, M Milella, C Coppola, V Messina, E Claar; citation_volume=39; citation_issue=10; citation_publication_date=2019; citation_pages=1852-1859; citation_doi=10.1111/liv.14170; citation_id=CR53 citation_journal_title=Adv Ther; citation_title=Safety and effectiveness using 8 weeks of glecaprevir/pibrentasvir in HCV-infected treatment-naïve patients with compensated cirrhosis: the CREST Study; citation_author=M Cornberg, A Ahumada, A Aghemo, M Andreoni, A Bhagat, I Butrymowicz; citation_publication_date=2022; citation_doi=10.1007/s12325-022-02158-6; citation_id=CR54 citation_journal_title=Liver Int; citation_title=Direct-acting antiviral interactions with opioids, alcohol or illicit drugs of abuse in HCV-infected patients; citation_author=K Ing Lorenzini, F Girardin; citation_volume=40; citation_issue=1; citation_publication_date=2020; citation_pages=32-44; citation_doi=10.1111/liv.14283; citation_id=CR55 US International Trade Commission. Deadly high-purity fentanyl from China is entering the U.S. through e-commerce channels. 2019. https://www.usitc.gov/publications/332/executive_briefings/ebot_george_serletis_fentanyl_from_china_pdf.pdf . citation_journal_title=J Hepatol; citation_title=Reported safety of HCV direct-acting antivirals with opioids: 2017 to 2021. Poster presentation (FRI411) at EASL; citation_author=AKT Martinez, DE Dylla; citation_publication_date=2022; citation_doi=10.1016/S0168-8278(22)01509-4; citation_id=CR57 citation_journal_title=Basic Clin Pharmacol Toxicol; citation_title=Fentanyl pharmacokinetics is not dependent on hepatic uptake by organic anion-transporting polypeptide 1b1 in human beings; citation_author=VC Ziesenitz, SK König, N Mahlke, R Jantos, G Skopp, J Weiss; citation_volume=113; citation_issue=1; citation_publication_date=2013; citation_pages=43-48; citation_doi=10.1111/bcpt.12066; citation_id=CR58 citation_journal_title=Clin Pharmacol Ther; citation_title=Rifampin's acute inhibitory and chronic inductive drug interactions: experimental and model-based approaches to drug–drug interaction trial design; citation_author=M Reitman, X Chu, X Cai, J Yabut, R Venkatasubramanian, S Zajic; citation_volume=89; citation_issue=2; citation_publication_date=2011; citation_pages=234-242; citation_doi=10.1038/clpt.2010.271; citation_id=CR59 citation_journal_title=Curr Top Med Chem; citation_title=Opioid analgesics and P-glycoprotein efflux transporters: a potential systems-level contribution to analgesic tolerance; citation_author=LS Mercer, A Coop; citation_volume=11; citation_issue=9; citation_publication_date=2011; citation_pages=1157-1164; citation_doi=10.2174/156802611795371288; citation_id=CR60 Smith HS. Opioid metabolism. Mayo Clin Proc. 2009;84(7):613–24. American Association for the Study of Liver Diseases (AASLD), Infectious Disease Society of America (IDSA). HCV guidance: recommendations for testing, managing, and treating hepatitis C. 2022. https://www.hcvguidelines.org/ . American Society of Addiction Medicine. Public policy statement on hepatitis C infection. 2017. https://www.asam.org/docs/default-source/public-policy-statements/pdff5b01a9472bc604ca5b7ff000030b21a.pdf?sfvrsn=0#:~:text=Current%20guidelines%2C%20therefore%2C%20by%20the,I%2C%20Level%20A).%E2%80%9D . Pawlotsky J-M, Negro F, Aghemo A, Berenguer M, Dalgard O, Dusheiko G, et al. EASL recommendations on treatment of hepatitis C: final update of the series. J Hepatol. 2020;73(5):1170–218.